Medellín, Colombia

Francisco Lopera

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignees: Banner Health, The General Hospital Corporation, The Schepens Eye Research Institute, Inc.. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Francisco Lopera: Innovator in Cognitive Health

Introduction

Francisco Lopera is a distinguished inventor based in Medellin, Colombia. He has made significant contributions to the field of cognitive health, particularly in the prevention and treatment of cognitive decline associated with dementia and neurodegeneration. His innovative work has garnered attention in both academic and medical communities.

Latest Patents

Lopera holds a patent for "Anti-ApoE antibodies and polynucleotides thereof - Methods and compositions for preventing or treating cognitive decline associated with dementia and/or mild cognitive impairment and/or neurodegeneration using antibodies, peptides, fusion proteins, or genome editing systems that modulate HSPG/heparin binding affinities of ApoE." This patent represents a crucial advancement in therapeutic strategies aimed at addressing cognitive decline.

Career Highlights

Throughout his career, Francisco Lopera has worked with notable organizations, including The General Hospital Corporation and Banner Health. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Lopera has collaborated with esteemed colleagues such as Yakeel T Quiroz and Joseph F Arboleda-Velasquez. These partnerships have further enriched his research and expanded the impact of his innovations.

Conclusion

Francisco Lopera's work in cognitive health exemplifies the importance of innovation in addressing complex medical challenges. His contributions through patents and collaborations continue to pave the way for advancements in the treatment of cognitive decline.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…